A Bioequivalence Study of 15 mg ER OROS Paliperidone
Status:
Completed
Trial end date:
2004-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the bioequivalence between the Phase 3 and the
to-be-marketed formulations of extended release (ER) OROS paliperidone and to evaluate the
effect of food on the highest to be marketed tablet strength. Additionally, the safety and
tolerability of the treatments in healthy volunteers will be assessed.
Phase:
Phase 1
Details
Lead Sponsor:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.